Hainan Poly Pharm. Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hainan Puli Pharmaceutical Co., Ltd. (Puli Pharmaceutical, stock code: 300630), founded in 1992, is a high-tech enterprise specializing in the research and development, production, and sales of generic and innovative drugs. It is one of the few leading enterprises in the internationalization of pharmaceutical preparations in China. It is a global oriented group company specializing in the research and development, production, and sales of chemical raw materials and pharmaceutical preparations. The production lines of the company's raw materials and freeze-dried powder injections have passed the cGMP and GMP audits of the relevant production quality standards (cGMP and GMP) of the US FDA, EU EMA, and WHO. The production lines of small volume injections and oral solid formulations have also passed the cGMP and GMP audits of the US FDA and EU EMA. The company's marketing network has covered thousands of hospitals, as well as multiple grassroots medical institutions and other medical terminals in various provinces, cities, and autonomous regions across the country, with over a thousand distributors and distributors. |
| Headquarter | Haikou |
| Establish Date | 7/14/1992 |
| Listed Code | 300630.SZ |
| Listed Date | 3/28/2017 |
| Chairman | Fan Minhua. |
| CEO | Fan Minhua. |
| Website | www.hnpoly.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
